STOCK TITAN
  1. Home
  2. News
  3. TBIO

Telesis Bio Inc - TBIO STOCK NEWS

Welcome to our dedicated news page for Telesis Bio (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on Telesis Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Telesis Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Telesis Bio's position in the market.

News
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Rhea-AI Summary
Telesis Bio Inc. (NASDAQ: TBIO) announces a strategic focus on its Gibson SOLA enzymatic DNA synthesis platform and BioXp mRNA solutions. The company aims to accelerate drug discovery by offering high-throughput solutions for DNA and mRNA synthesis, targeting vaccine and therapeutic candidates. Telesis Bio has secured collaborations to expand the adoption of its platforms and has restructured operations to achieve cost savings. Additionally, the company appoints Eric Esser as the new CEO, replacing Todd R. Nelson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Telesis Bio Inc. (TBIO) reported strong financial results for Q4 and full-year 2023, showcasing record BioXp kit sales, expanding gross margin, and reduced operating expenses. The company achieved $1.0 million in BioXp kit revenue for Q4, a 59.6% increase from the prior quarter. Total revenue for 2023 was $27.5 million, slightly up from 2022. Collaboration revenue increased by 30.7% to $8.7 million. Operating expenses were reduced by 16.1% in 2023. The company completed cost reduction activities and insourced oligo supply, expecting favorable impacts on gross margin in 2024. Despite a net loss of $18.3 million in Q4, the company remains focused on strategic collaborations and product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
earnings
-
News
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Rhea-AI Summary
Telesis Bio Inc. announces strong financial results for Q4 and full-year 2023, with BioXp kit sales exceeding $1.0 million in Q4, a 59.6% increase from the prior quarter. Total revenue for the year is expected to be $27.5 million, up slightly from 2022, driven by increased BioXp kit sales and collaboration revenue. Gross margin is expected to exceed 60.0%, up from 56.8% in 2022, due to an improving product mix and high margin collaboration revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
earnings
News
Telesis Bio Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Telesis Bio Inc. (NASDAQ: TBIO) reported financial results for Q3 2023. The company highlighted the strengthening of its board and management team, the successful launch of the BioXp NGS Library Prep Kit, and operational milestones. Q3 2023 financial results showed a 16.6% reduction in revenue and a net loss of $10.6 million. However, the company maintained a strong gross margin and successfully reduced operating expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
earnings
-
News
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
Rhea-AI Summary
Telesis Bio (Nasdaq: TBIO) will release its third quarter 2023 financial results on November 13, 2023, after the market closes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
conferences earnings
-
News
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
Rhea-AI Summary
Telesis Bio Inc. has announced the commercial release of its BioXp® De novo Cloning and Amplification kit, offering an automated solution for building and amplifying DNA constructs. The kit eliminates the need for bacterial scale-up and unpredictable service provider delivery times, allowing researchers to progress from sequence to functional screening in days instead of weeks. This new addition to their DNA amplification kits empowers researchers in iterative discovery applications and provides workflow stability, control, and efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
News
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
Rhea-AI Summary
Telesis Bio Inc. releases BioXp NGS Library Prep kit for Whole Genome Sequencing, expanding their suite of NGS Library Preparation solutions on the BioXp platform. The kit enables automated library preparation of up to 96 genomic DNA samples, reducing hands-on time and cost. This is expected to streamline the NGS Library Preparation workflow and accelerate genomics discovery workflows.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
News
Telesis Bio Appoints William J. Kullback Chief Financial Officer
Rhea-AI Summary
Telesis Bio Inc. appoints William J. Kullback as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
management
-
News
Telesis Bio Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Telesis Bio Inc. (NASDAQ: TBIO) reported a 53% year-over-year increase in total revenue to $8.7M in 2QFY23. The company achieved milestones in revenue growth, gross margin expansion, and operating expenses reduction. Additionally, they raised $28M in financing and strengthened their board of directors. Telesis Bio also successfully launched three BioXp® kits and achieved operational milestones, including vertical integration of manufacturing. Despite a net loss of $8.3M, the company reduced operating expenses while growing revenue year over year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
earnings
News
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences earnings
Stock TBIO logo
Telesis Bio Inc

Nasdaq:TBIO

TBIO Rankings

N/A Ranked by Market Cap
#4780 Ranked by Stock Gains
N/A Ranked by Dividends

TBIO Stock Data

12.34M
9.26M
37.35%
38.22%
0.33%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
San Diego

About TBIO

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.